Argos Therapeutics to discontinue the ADAPT trial
Argos Therapeutics reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for treatment of newly diagnosed metastatic renal cell carcinoma. April 19, 2018